HM 95573

Drug Profile

HM 95573

Alternative Names: HM95573; RG 6185

Latest Information Update: 20 May 2017

Price : $50

At a glance

  • Originator Hanmi Pharmaceutical
  • Class Antineoplastics
  • Mechanism of Action Proto oncogene protein b raf inhibitors; Proto oncogene proteins c raf inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Solid tumours

Most Recent Events

  • 21 Apr 2017 Hanmi Pharmaceutical plans a phase I trial for Solid tumours (Monotherapy) in South Korea (NCT03118817)
  • 29 Sep 2016 Hanmi Pharmaceutical enters into an license agreement with Genentech to obtain worldwide rights, excluding South Korea for HM 95573
  • 01 Jan 2015 Phase-I clinical trials in Solid tumours (Late-stage disease) in South Korea (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top